Skip to Content

Global Insights from MATTERHORN: Unifying Gastric Cancer Treatment Standards with Durvalumab and FLOT

In this MEDtalk, Dr. Janjigian presents a comprehensive analysis from the global MATTERHORN study, showcased at ASCO GI. The study investigates the efficacy of durvalumab in combination with the FLOT regimen for treating localized, non-metastatic gastric and gastroesophageal adenocarcinoma. The study’s international scale is noteworthy, incorporating a diverse cohort of patients from Asia, Europe, and both South and North America. This extensive reach underscores the study’s potential to standardize gastric cancer treatment protocols across various geographic regions, thereby harmonizing the management strategies despite regional differences in disease presentation and response to therapy.

Yelena Janjigian

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top